PT3119794T - Formulação que compreende um pró-fármaco de gemcitabina - Google Patents

Formulação que compreende um pró-fármaco de gemcitabina

Info

Publication number
PT3119794T
PT3119794T PT157334988T PT15733498T PT3119794T PT 3119794 T PT3119794 T PT 3119794T PT 157334988 T PT157334988 T PT 157334988T PT 15733498 T PT15733498 T PT 15733498T PT 3119794 T PT3119794 T PT 3119794T
Authority
PT
Portugal
Prior art keywords
gemcitabine
prodrug
formulation
Prior art date
Application number
PT157334988T
Other languages
English (en)
Inventor
Griffith Hugh
Kennovin Gordon
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of PT3119794T publication Critical patent/PT3119794T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT157334988T 2014-06-25 2015-06-25 Formulação que compreende um pró-fármaco de gemcitabina PT3119794T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2050MU2014 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives

Publications (1)

Publication Number Publication Date
PT3119794T true PT3119794T (pt) 2018-01-15

Family

ID=53499028

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157334988T PT3119794T (pt) 2014-06-25 2015-06-25 Formulação que compreende um pró-fármaco de gemcitabina

Country Status (29)

Country Link
US (4) US10117888B2 (pt)
EP (2) EP3119794B1 (pt)
JP (3) JP6855248B2 (pt)
KR (2) KR20220104270A (pt)
CN (2) CN106470672B (pt)
AU (2) AU2015278900B2 (pt)
BR (1) BR112016025787B1 (pt)
CA (1) CA2944966C (pt)
CL (1) CL2016003261A1 (pt)
CY (1) CY1119772T1 (pt)
DK (1) DK3119794T3 (pt)
EA (1) EA033046B1 (pt)
ES (1) ES2655820T3 (pt)
HK (1) HK1244437A1 (pt)
HR (1) HRP20180007T1 (pt)
HU (1) HUE036011T2 (pt)
IL (2) IL248345B (pt)
LT (1) LT3119794T (pt)
MX (2) MX2020004054A (pt)
MY (1) MY186584A (pt)
NO (1) NO3119794T3 (pt)
PH (1) PH12016502552A1 (pt)
PL (1) PL3119794T3 (pt)
PT (1) PT3119794T (pt)
RS (1) RS56752B1 (pt)
SG (1) SG11201608809RA (pt)
SI (1) SI3119794T1 (pt)
TW (2) TWI674097B (pt)
WO (1) WO2015198059A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
PL3447061T3 (pl) 2011-03-01 2022-01-31 NuCana plc Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
RS58849B1 (sr) 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
WO2015198058A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
CN106470672B (zh) * 2014-06-25 2019-11-05 努卡那生物医药有限责任公司 包括吉西他滨前药的制剂
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
KR20230098915A (ko) 2014-11-28 2023-07-04 뉴카나 피엘씨 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106539810B (zh) * 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
MX2018004137A (es) 2015-10-05 2018-06-13 NuCana plc Terapia de combinacion.
EP4011896A1 (en) 2015-12-11 2022-06-15 NuCana plc Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
CA3041121A1 (en) 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
MX2020000488A (es) 2017-07-20 2020-10-28 Centrexion Therapeutics Corp Metodos y composiciones para el tratamiento del dolor usando capsaicina.
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE60042073D1 (de) 1999-07-22 2009-06-04 Celmed Oncology Usa Inc Enzym katalisierte therapeutische aktivierung
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2006081364A2 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including ndga compounds, into animals
US8492400B2 (en) * 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
EP1913962A1 (en) * 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
WO2011008985A2 (en) * 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
MX2012005677A (es) * 2009-11-20 2012-08-23 Clavis Pharma Asa Formulaciones parentales de derivados de gemcitabina.
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
EP2804582B1 (en) * 2012-01-20 2016-03-30 Aratana Therapeutics NV Eye drop composition
CA2890359A1 (en) * 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
RS58849B1 (sr) 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
WO2015198058A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
CN106470672B (zh) 2014-06-25 2019-11-05 努卡那生物医药有限责任公司 包括吉西他滨前药的制剂
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3197456B2 (en) 2015-05-14 2023-10-11 NuCana plc Cancer treatments
MX2018004137A (es) 2015-10-05 2018-06-13 NuCana plc Terapia de combinacion.
EP4011896A1 (en) 2015-12-11 2022-06-15 NuCana plc Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
WO2017109486A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
TW201613611A (en) 2016-04-16
US11707477B2 (en) 2023-07-25
TW201945007A (zh) 2019-12-01
MX2016015629A (es) 2017-08-02
NO3119794T3 (pt) 2018-03-10
IL248345B (en) 2020-10-29
PL3119794T3 (pl) 2018-04-30
MY186584A (en) 2021-07-28
US20170095498A1 (en) 2017-04-06
SI3119794T1 (en) 2018-02-28
US20190022118A1 (en) 2019-01-24
CY1119772T1 (el) 2018-06-27
KR102421929B1 (ko) 2022-07-15
LT3119794T (lt) 2018-02-12
CA2944966C (en) 2022-10-25
DK3119794T3 (en) 2018-01-22
US10786523B2 (en) 2020-09-29
NZ725009A (en) 2021-02-26
TWI765176B (zh) 2022-05-21
BR112016025787A2 (pt) 2017-08-15
AU2015278900B2 (en) 2019-04-04
KR20220104270A (ko) 2022-07-26
EP3119794A1 (en) 2017-01-25
PH12016502552A1 (en) 2017-04-10
JP6855248B2 (ja) 2021-04-07
IL248345A0 (en) 2016-11-30
SG11201608809RA (en) 2016-11-29
CA2944966A1 (en) 2015-12-30
US20220031727A1 (en) 2022-02-03
EP3269391A1 (en) 2018-01-17
IL276199B (en) 2022-04-01
ES2655820T3 (es) 2018-02-21
JP7329025B2 (ja) 2023-08-17
CN106470672B (zh) 2019-11-05
HUE036011T2 (hu) 2018-06-28
AU2019204557B2 (en) 2020-08-27
US20200397810A1 (en) 2020-12-24
JP6970221B2 (ja) 2021-11-24
IL276199A (en) 2020-09-30
AU2015278900A1 (en) 2016-10-27
AU2019204557A1 (en) 2019-07-18
HRP20180007T1 (hr) 2018-02-23
CN110882268A (zh) 2020-03-17
CL2016003261A1 (es) 2017-10-06
JP2020079255A (ja) 2020-05-28
WO2015198059A1 (en) 2015-12-30
HK1244437A1 (zh) 2018-08-10
BR112016025787B1 (pt) 2022-12-13
JP2017519022A (ja) 2017-07-13
US11040051B2 (en) 2021-06-22
MX2020004054A (es) 2021-11-30
CN106470672A (zh) 2017-03-01
KR20170042501A (ko) 2017-04-19
EP3119794B1 (en) 2017-10-11
EA033046B1 (ru) 2019-08-30
EA201692422A1 (ru) 2017-04-28
US10117888B2 (en) 2018-11-06
TWI674097B (zh) 2019-10-11
RS56752B1 (sr) 2018-04-30
JP2022031659A (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
IL276199B (en) The composition containing gemcitabine-meter drug
ZA201608424B (en) A micellar nanocomplex
HK1214981A1 (zh) 微型加濕器
GB201407934D0 (en) Formulation
PL3107946T3 (pl) Poliizomocznik
IL248835A0 (en) A preparation of ciritinib
IL248174A0 (en) Agrochemical formulations
IL251362A0 (en) formulation
GB201518909D0 (en) A formulation
GB2517601B (en) A plinth
GB201402448D0 (en) Novel formulation
GB201402247D0 (en) A footgauge
GB201511301D0 (en) Formulation
GB201416247D0 (en) A formulation
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation
GB201419012D0 (en) A composition
GB201414050D0 (en) A composition
GB201404865D0 (en) A Hydrogenerator
GB201411681D0 (en) Concept a
GB201400958D0 (en) n/a
GB201400532D0 (en) Metix limited COREMED A
GB201404151D0 (en) A duster